Bevacizumab in Metastatic Renal Cancer

Roche

Status: Completed

Conditions: Renal Cell Cancer

Treatments: Drug: Bevacizumab; Drug: Interferon alpha-2a

Study type: Observational

Funder types: Industry

Identifiers

NCT02627144

ML21519

Details and patient eligibility

About

This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.

Enrollment: 365 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed advanced and/or metastatic renal cell cancer
• No contraindications for Avastin according to summary of product characteristics (SmPC)

Exclusion criteria

Trial design

365 participants in 1 patient group

Advanced and/or Metastatic RCC participants

Description:

Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.

Treatment:

Drug: Bevacizumab

Drug: Interferon alpha-2a